Related Experiment Video
Updated: Jun 18, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Lipodystrophy and metabolic complications of highly active antiretroviral therapy
Ankit Parakh1, Anand Prakash Dubey, Ajay Kumar
1Department of Pediatrics, Maulana Azad Medical College and Associated Hospitals, New Delhi, India. ankitparakh102@rediffmail.com
Insights
Metabolic abnormalities and lipodystrophy are emerging complications in Indian children receiving first-line highly active antiretroviral therapy (HAART). Close follow-up is crucial for managing these potential side effects.
Area of Science:
- Pediatric infectious diseases
- Pharmacology and toxicology
- Metabolic disorders
Background:
- Highly active antiretroviral therapy (HAART) is the standard of care for HIV-infected children.
- Understanding the metabolic toxicities of first-line HAART regimens is essential for long-term patient management.
- Body fat redistribution (lipodystrophy) is a known concern with antiretroviral drugs.
Purpose of the Study:
- To evaluate metabolic drug toxicities associated with WHO-recommended generic HAART in children.
- To determine the prevalence of body fat redistribution (lipoatrophy and lipohypertrophy) in this population.
- To identify risk factors contributing to these adverse effects.
Main Methods:
- A cross-sectional observational study involving 52 HIV-infected children (25 on HAART, 27 controls).
- Assessment included sociodemographic, clinical, and immunological data.
- Physical examination for lipodystrophy, and laboratory tests for liver function, blood sugar, lipids, amylase, lactate, pH, and bicarbonate.
Main Results:
- Children on HAART (stavudine/zidovudine-based) showed lower weight-for-age and BMI, but similar height-for-age compared to controls.
- Two cases of peripheral lipoatrophy and four cases of hypercholesterolemia were observed in the HAART group.
- Asymptomatic mild hyperlactatemia occurred in four children; no hyperglycemia or liver impairment was noted.
Conclusions:
- Metabolic abnormalities and lipodystrophy are emerging complications of HAART in Indian children.
- These findings highlight the need for vigilant monitoring and follow-up.
- Larger, longitudinal studies are recommended to further elucidate these complications.
Objective:
To assess the metabolic drug toxicities of first-line, World Health Organization (WHO)-recommended generic highly active antiretroviral therapy (HAART) regimens, to estimate the prevalence of body fat redistribution and to identify associated risk factors.
Methods:
Cross-sectional observational study. During 3 month period, 52 HIV infected children (25 on HAART; 27 not on HAART) were assessed. Their sociodemographic, clinical, and immunological data was recorded. Children were examined or the signs of fat redistribution (peripheral lipoatrophy and central lipohypertrophy). Liver function tests, fasting blood sugar, lipid profile, serum amylase, serum lactate, blood pH and bicarbonate levels were done in all patients.
Results:
Twenty-two patients were on stavudine and three on zidovudine based HAART. None of the patients ever received any protease inhibitor. There were no cases of clinical or immunological failure. Children on HAART had significantly lower weight for age and body mass index but the mean height for age was similar between study groups. Only two cases of peripheral lipoatrophy were observed. Hypercholesterolemia was observed in four children on HAART but none without therapy. Hypertriglyceridemia was observed in three children on HAART and seven without therapy. Four cases of asymptomatic mild hyperlactatemia were observed. No case of any hyperglycemia or liver impairment was observed.
Conclusion:
Metabolic abnormalities and lipodystrophy are emerging complications of HAART in Indian children and needs very close follow up. Future studies with larger sample size and longitudinal model are recommended.
Related Concept Videos
Retrovirus Life Cycles
Complications of Diabetes Mellitus
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Type II Diabetes II: Pathophysiology
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

